Hypogonadism in Benign Prostate Hyperplasia: A Cross Sectional Study: Hypogonadism in Benign Prostate Hyperplasia

Ismail  Khan; Malik  Aftab Younus; Mohammad  Shoaib; Muhammad  Haris; Noman  Ullah Wazir; Muhammad  Jehangir Khan; Sobia  Haris; Farah  Deeba

doi:10.54393/pjhs.v3i03.66

Authors

Ismail Khan Department of Urology, Peshawar Medical College, Peshawar, Pakistan
Malik Aftab Younus Department of Urology, Fazaia Ruth Pfau Medical College, Karachi, Pakistan
Mohammad Shoaib Department of Urology, Peshawar Medical College, Peshawar, Pakistan
Muhammad Haris Department of Anatomy, Nowshera Medical College, Nowshera, Pakistan
Noman Ullah Wazir Department of Anatomy, Peshawar Medical College, Peshawar, Pakistan
Muhammad Jehangir Khan Department of Pediatric Surgery, Makka Medical Center, Nowshera, Pakistan
Sobia Haris Department of Medical Education, Nowshera Medical College, Nowshera, Pakistan
Farah Deeba Department of Medical Education, Nowshera Medical College, Nowshera, Pakistan.

DOI:

https://doi.org/10.54393/pjhs.v3i03.66

Keywords:

Hypogonadism, Benign Prostate Hyperplasia

Abstract

Benign prostatic hyperplasia is a common health problem affecting men older than 50 years. It is estimated that 30 million men have benign prostatic hyperplasia related clinical features Objective: The objective of this study was to find out the relationship between hypogonadism in patients presenting with benign prostate hyperplasia at tertiary care center. Methods: A descriptive cross-sectional study conducted at Urology Department Lady Reading Hospital Peshawar for a period of one year from June 2019 to May 2020. A total of 361 patients with benign prostate hyperplasia were studied. The sampling technique was consecutive non probability sampling and WHO sample size calculator was used for sample size determination. Serum testosterone level was done all patients as per inclusion criteria. All the data was analyzed in SPSS version 20.0. Results: The mean age, height weight, BMI and testosterone level of qualitative variables were 56.42±10.05, 167.54±9.97, 64.96±12.92, 23.07±4.96 and 15.36±6.36 respectively. The testosterone level decreased with ageing in different age groups. 29.6% patients of our study were 50-59 years old. The hypertensive and diabetic patients with BPH were 31.3% and 22.4% respectively. Out of 361 patients 67 were hypo gonadal men making 18.6%. The hypogonadism had statistically significant mean values of serum testosterone level (p<0.001). Conclusions: This study concluded on the analytical findings that hypogonadism is significantly associated with benign prostate hyperplasia. The testosterone levels decrease with the increase of age and thus patients with low testosterones are more prone to develop benign prostate hyperplasia.

References

Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urologic Clinics of North America. 2016 Aug; 43(3):289-97. doi: 10.1016/j.ucl.2016.04.001.

Xia BW, Zhao SC, Chen ZP, Chen C, Liu TS, Yang F, et al. Relationship between serum total testosterone and prostate volume in aging men. Scientific reports. 2021 Jul; 11(1):14122. doi: 10.1038/s41598-021-93728-1.

Kopp W. Diet-Induced Hyperinsulinemia as a Key Factor in the Etiology of Both Benign Prostatic Hyperplasia and Essential Hypertension? Nutrition and Metabolic Insights. 2018 May; 11:1178638818773072. doi: 10.1177/1178638818773072

Park JS, Koo KC, Kim HK, Chung BH, Lee KS. Impact of metabolic syndrome-related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms in Asian population. Medicine (Baltimore). 2019 Oct; 98(42): e17635. doi: 10.1097/MD.0000000000017635.

Wei L, Lai EC, Kao-Yang YH, Walker BR, MacDonald TM, Andrew R. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study. British medical journal 2019 Apr; 365: l1204. doi: 10.1136/bmj. l1204.

Wichendu PN, Odum EP, Amadi C, Aleme BM. Endogenous testosterone to prostate-specific antigen relationship in men without prostatic diseases: a 10-year retrospective study. International Surgery Journal. 2018 Mar; 5(4):1186-91.

Handelsman DJ. Mechanisms of action of testosterone--unraveling a Gordian knot. New England Journal of Medicine. 2013 Sep; 369(11):1058-9. doi: 10.1056/NEJMe1305307.

Bechis SK, Otsetov AG, Ge R, Olumi AF. Personalized medicine for the management of benign prostatic hyperplasia. The Journal of urology. 2014 Jul; 192(1):16-23. doi: 10.1016/j.juro.2014.01.114.

Nicholson TM and Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 2011 Dec; 82(4-5):184-99. doi: 10.1016/j.diff.2011.04.006.

Jarvis TR, Chughtai B, Kaplan SA. Testosterone and benign prostatic hyperplasia. Asian journal of andrology. 2015 Apr; 17(2):212-6. doi: 10.4103/1008-682X.140966.

Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2010 Jun; 95(6):2536-59. doi: 10.1210/jc.2009-2354.

Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer: from physiology to clinical implications. European Urology. 2014 Jan; 65(1):115-23. doi: 10.1016/j.eururo.2013.08.015.

Pexman-Fieth C, Behre HM, Morales A, Kan-Dobrosky N, Miller MG. A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel. Aging Male. 2014 Mar; 17(1):1-11. doi: 10.3109/13685538.2013.858113.

Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M. Benign prostatic hyperplasia: a new metabolic disease? Journal of Endocrinological Investigation. 2014 Apr; 37(4):313-22. doi: 10.1007/s40618-014-0051-3.

Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. Journal of urology. 1991 Feb; 145(2):405-9. doi: 10.1016/s0022-5347(17)38353-2.

Griffiths K, Eaton CL, Harper ME, Peeling B, Davies P. Steroid hormones and the pathogenesis of benign prostatic hyperplasia. European Urology. 1991; 20 Suppl 1:68-77. doi: 10.1159/000471750.

Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. Journal of urology. 2004 Oct; 172(4 Pt 1):1399-403. doi: 10.1097/01.ju.0000139539.94828.29.

Montie JE and Pienta KJ. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology. 1994 Jun; 43(6):892-9. doi: 10.1016/0090-4295(94)90163-5.

Sciarra F and Toscano V. Role of estrogens in human benign prostatic hyperplasia. Archives of andrology. 2000 Jun; 44(3):213-20. doi: 10.1080/014850100262191.

Ho CK and Habib FK. Estrogen and androgen signaling in the pathogenesis of BPH. Nature reviews. Urology. 2011 Jan; 8(1):29-41. doi: 10.1038/nrurol.2010.207.

Joseph MA, Wei JT, Harlow SD, Cooney KA, Dunn RL, Jaffe CA, et al. Relationship of serum sex-steroid hormones and prostate volume in African American men. Prostate. 2002 Dec; 53(4):322-9. doi: 10.1002/pros.10154.

Meikle AW, Stephenson RA, Lewis CM, Middleton RG. Effects of age and sex hormones on transition and peripheral zone volumes of prostate and benign prostatic hyperplasia in twins. Journal of Clinical Endocrinology and Metabolism. 1997 Feb; 82(2):571-5. doi: 10.1210/jcem.82.2.3720.

Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. Journal of urology. 2002 Aug; 168(2):599-604.

Glynn RJ, Campion EW, Bouchard GR, Silbert JE. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. American journal of epidemiology. 1985 Jan; 121(1):78-90.

Sidney S, Quesenberry CP Jr, Sadler MC, Guess HA, Lydick EG, Cattolica EV. Incidence of surgically treated benign prostatic hypertrophy and of prostate cancer among blacks and whites in a prepaid health care plan. American journal of epidemiology.1991 Oct; 134(8):825-9. doi: 10.1093/oxfordjournals.aje.a116157.

Wang S, Mao Q, Lin Y, Wu J, Wang X, Zheng X, et al. Body mass index and risk of BPH: a meta-analysis. Prostate cancer and prostatic diseases. 2012 Sep; 15(3):265.

Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. International Journal of Endocrinology. 2014;

Hammarsten J and Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. European Urology. 2001; 39(2):151-8.

Xin C, Fan H, Xie J, Hu J, Sun X, Liu Q. Impact of diabetes mellitus on lower urinary tract symptoms in benign prostatic hyperplasia patients: a meta-analysis. Frontiers in endocrinology. 2022 Feb; 12:741748.

Kopp W. Diet-induced hyperinsulinemia as a key factor in the etiology of both benign prostatic hyperplasia and essential hypertension? Nutrition and Metabolic Insights. 2018 May; 11:1178638818773072.

Anwar AR and Basha AA. Benign prostatic hyperplasia and its association with ABO blood group system. Journal of medical science and clinical research. 2015; 3:6095-9.

Zeng XT, Weng H, Xiong J, Huang Q, Ma LL, Jin YH, et al. Comparison of clinical and physiological parameters for benign prostatic hyperplasia in hypertensive and normotensive patients. Frontiers in Physiology. 2018 Sep; 9:1330.